A novel indanyl-propargylamine featuring an indane core with an N-propargyl substituent. This compound shows strong potential as a CNS-active MAO inhibitor with favorable physicochemical and pharmacokinetic properties.
[1-(2,3-dihydro-1H-inden-1-yl)ethyl](prop-2-yn-1-yl)amine
C14H17N
199.30 g/mol
199.1361
C: 84.37%, H: 8.60%, N: 7.03%
Not assigned (novel compound)
-3.13
2.88
1.08
9.21
1
1
4
≈ 12 Ų
CC(C1c2ccccc2CC1)NCC#C
Predicted solubility and lipophilicity profiles suggest balanced amphiphilicity—low aqueous solubility but suitable membrane permeability for CNS penetration.
Reductive amination of 1-(2,3-dihydro-1H-inden-1-yl)ethanone with propargylamine, followed by reduction with NaBH₃CN.
Reaction of 1-(2,3-dihydro-1H-inden-1-yl)ethan-1-amine with propargyl bromide in the presence of base (e.g. Na₂CO₃) in acetonitrile.
MAO inhibition studies, neuroprotective agent screening, and CNS pharmacokinetics research.
Investigational use for Parkinson’s disease, depression, ADHD, and related neuropsychiatric disorders.
Prototype scaffold for propargylamine-based MAO inhibitors; potential salt forms include HCl, mesylate, and fumarate.